Cost–Utility of All-Oral Direct-Acting Antiviral Regimens for the Treatment of Genotype 1 Chronic Hepatitis C Virus-Infected Patients in Hong Kong

Background Direct-acting antivirals (DAAs) are entering the hepatitis C virus (HCV) treatment landscape in Hong Kong, prompting the need for cost–effectiveness evaluations of these interventions to enable optimal use of healthcare resources. Aims This study aimed to compare the cost–effectiveness of...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Digestive diseases and sciences 2021-04, Vol.66 (4), p.1315-1326
Hauptverfasser:	Yuen, Man-Fung, Liu, Sze-Hang, Seto, Wai-Kay, Mak, Lung-Yi, Corman, Shelby L., Hsu, Danny C., Lee, Mary Y. K., Khan, Tsz K., Puenpatom, Amy
Format:	Artikel
Sprache:	eng
Schlagworte:	Analysis Antiviral agents Antiviral drugs Biochemistry Biological response modifiers Economic aspects Gastroenterology Gastroenterology & Hepatology Genotype & phenotype Hepatitis Hepatitis C Hepatitis C virus Hepatology Interferon Life Sciences & Biomedicine Liver Liver cancer Liver cirrhosis Markov processes Medical care Medicine Medicine & Public Health Oncology Original Original Article Protease inhibitors Quality management Science & Technology Transplant Surgery Transplantation of organs, tissues, etc
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!